Surgery Today https://doi.org/10.1007/s00595-026-03499-3 ORIGINAL ARTICLE Coronary bypass outcomes in chronic limb-threatening ischemia are significantly worse than in patients with non-critical lower extremity arterial disease Kentaro Shirakura1 · Yuki Setogawa1 · Ryohei Ushioda1 · Daisuke Takeyoshi1 · Masahiro Tsutsui1,2 · Shinsuke Kikuchi3 · Nobuyoshi Azuma3 · Hiroyuki Kamiya1 · Shingo Kunioka1 Received: 10 May 2026 / Accepted: 18 September 2026 © The Author(s) 2026 Abstract Purpose Lower extremity arterial disease (LEAD) is a risk factor in patients undergoing coronary artery bypass grafting (CABG); however, the impact of chronic limb-threatening ischemia (CLTI), its most advanced stage, remains unclear. We evaluated early and long-term outcomes of CABG in CLTI. Method We retrospectively analyzed 334 consecutive patients who underwent isolated CABG between 2014 and 2024. Patients were stratified into three groups: CLTI (n = 22), non-CLTI LEAD (n = 41), and non-LEAD (n = 271). The primary endpoint was long-term survival; the secondary endpoints were 30-day mortality and major adverse cardiac and cerebrovascular events. Results The CLTI group had higher rates of diabetes mellitus (90.9%) and hemodialysis (86.4%) (p < 0.01). Thirty-day mortality was similar (9.1%, 2.4%, and 5.5%; p = 0.52), whereas five-year survival was significantly lower in the CLTI group (39.8% vs. 86.2% and 90.8%; p < 0.01). A Cox analysis showed that age, hemodialysis, and acute myocardial infarction were independent predictors of 5-year survival. Conclusions CLTI predicts poor long-term survival because of comorbidities. In this high-risk population, individualized strategies balancing the extent of coronary revascularization against operative risk may achieve acceptable early outcomes, although the safety of incomplete/functional revascularization requires confirmation in larger cohorts. Keywords CLTI · CABG · LEAD Introduction Lower extremity arterial disease (LEAD) is a well-established risk factor for coronary artery bypass grafting (CABG) [1–3], reflected as a binary variable in risk scoring systems Ryohei Ushioda ryouheihei98@gmail.com 1 Department of Cardiac Surgery, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan 2 Department of Cardiovascular Surgery, Asahikawa Red Cross Hospital, 1-1-1 Akebono 1 Jo, Asahikawa, Hokkaido 070-8530, Japan 3 Department of Vascular Surgery, Asahikawa Medical University, Asahikawa 078-8510, Japan such as the STS score, EuroSCORE II, and Japan SCORE. However, LEAD severity varies and is not reflected in current scoring systems. Chronic limb-threatening ischemia (CLTI), the most advanced form of LEAD, is characterized by rest pain, gangrene, or ulceration >2 weeks, is associated with high mortality and amputation, with a 2-year survival of 60%–65% [4–6]. Whether CLTI adversely affects CABG outcomes remains unclear. Our institution is a high-volume CLTI center in Japan that actively performs lower extremity revascularization using surgical bypass and endovascular therapy. Based on this experience, we developed a multidisciplinary “Heart-Limb Team” strategy incorporating minimally invasive techniques to optimize outcomes for patients with concomitant coronary artery disease and CLTI [4, 5]. We investigated CABG outcomes in CLTI patients compared with non-CLTI LEAD and non-LEAD patients Surgery Today and evaluated whether CLTI represents an independent risk factor for CABG. Methods Between April 2014 and April 2024, 573 patients underwent CABG at our institution. After excluding 239 patients who underwent concomitant procedures, 334 patients with isolated CABG were analyzed. Patients were stratified by LEAD status into three groups (Fig. 1): CLTI (n = 22), non-CLTI LEAD (n = 41), and non-LEAD (n = 271). Postoperative coronary angiography or computed tomography angiography was performed within 1 week after surgery to evaluate early graft patency, except when clinically contraindicated or declined. The primary endpoint was long-term survival; the secondary endpoints were 30-day mortality and major adverse cardiac and cerebrovascular events (MACCE). Independent censoring was assumed in the Kaplan–Meier and Cox proportional hazards analyses. Patients were censored on the last date they were known to be alive or at the end of follow-up. Surgical procedure and CABG strategy at our institution CABG was performed via median sternotomy or left minithoracotomy, primarily with on-pump arrest. LITA was routinely used for the left anterior descending artery. Additional revascularization was achieved with sequential SVG or a second arterial conduit (right internal thoracic or radial artery), particularly in patients <70 years. Internal thoracic arteries were harvested in a pedicled fashion; SVGs were generally skeletonized. Sequential or composite grafting was used as appropriate to optimize conduit use. Definition of significant coronary stenosis and complete revascularization Significant coronary stenosis was defined as ≥70% luminal narrowing or ≥50% for left main disease, based on quantitative assessment by the interventional cardiology team [7]. Complete revascularization was defined as grafting of all significant stenotic vessels. For multi-vessel diseases within the same territory, bypass to the largest target vessel responsible for the ischemic area was prioritized to achieve functional revascularization. Left main disease required grafting of both the LAD and LCX systems. Evaluation of limb ischemia severity LEAD was defined according to the Global vascular guidelines as ABI ≤0.90 or imaging evidence of lower-extremity arterial stenosis/occlusion. CLTI was defined as LEAD with rest pain, non-healing ulcer, or gangrene lasting >2 weeks [6]. Patients who previously met CLTI criteria but improved were reclassified as Non-CLTI LEAD (n = 6). Heart-limb team strategies The Heart-Limb Team, comprising cardiac and vascular surgeons, prioritized a 'Limb-First through Heart-First' strategy: (1) CABG as a prerequisite for limb-salvage surgery in patients with critical ischemia and stable coronary status, or (2) CABG to prevent death in patients at imminent risk of a coronary event. Patient selection was determined through multidisciplinary discussion; those with uncontrollable systemic infection (e.g., severe foot osteomyelitis) were managed with endovascular or palliative therapy. Statistical analysis Continuous variables are presented as the mean ± SD or median (IQR) and compared using ANOVA or Kruskal– Wallis test; categorical variables by chi-square or Fisher’s exact test with Bonferroni post hoc correction. Survival was estimated by the Kaplan–Meier method and compared using a log-rank test. Cox regression identified independent predictors of 5-year survival. Variables with p values < 0.10 in a univariable analysis or clinical relevance were included; multicollinearity was assessed by the variance inflation factor. All tests were two-sided; p values < 0.05 were considered significant. All analyses were performed using Stata (StataCorp, College Station, TX). Fig. 1 Study flow diagram. 334 isolated CABG patients were classified into CLTI (n = 22), Non-CLTI LEAD (n = 41), and Non-LEAD (n = 271) groups. CABG, coronary artery bypass grafting; CLTI, chronic limb-threatening ischemia; LEAD, lower extremity arterial disease 13 Surgery Today Ethical standard This study was approved by the Ethics Committee of our hospital on April 13, 2023 (Approval No. 22161). Owing to the retrospective observational design, the requirement for informed consent was waived by the Ethics Committee. Results The demographic characteristics are shown in Table 1. Age and sex were similar across groups, but preoperative risk scores were significantly higher in the CLTI group. DM and hemodialysis were more prevalent in the CLTI group (both p < 0.01). Preoperative mechanical circulatory support and acute AMI rates were comparable. Regarding the WIfI classification, grade 2–3 wounds were observed in 14 cases (63.6%), grade 2–3 ischemia in 19 cases (86.4%), grade 2–3 foot infection in 12 cases (54.5%), and WIfI clinical stage 4 in 14 cases (63.6%). The median Clinical Frailty Scale (CFS) score was significantly higher in the CLTI group (4.5 [3.8–7.0]) than in the Non-CLTI LEAD (3.0 [3.0–5.0]) and Non-LEAD (3.0 [2.2–3.8]) (p < 0.01) groups, and the Geriatric Nutritional Risk Index (GNRI) also differed significantly among the three groups (89.3 [80.6–90.8] vs. 87.3 [75.9–95.3] vs. 98.3 [90.8–98.3]; p < 0.01). Operative data are presented in Table 2. Left mini-thoracotomy was more common in the CLTI group; BITA use Table 1 Patients’ characteristics and preoperative data Variable CLTI group Non-CLTI LEAD group Non-LEAD group P-value n=22 n=41 n=271 Age, mean ± SD years 66.3±9.2 70.8±10.7 69.9 ± 10.2 0.15 Male gender, n (%) 18 (81.8) 32 (78.1) 196 (72.3) 0.49 BMI, kg/m2, mean ±SD 24.2 ± 4.0 24.2 ± 4.1 24.9 ± 4.4 0.31 Japan SCORE (Median[IQR]) 5.3 [2.37–17.3] 5.3 [1.3–9.9] 2.5 [1.0–7.5] < 0.01 Euro SCORE II (Median[IQR]) 4.8 [2.2–14.3] 3.3 [1.0–8.0] 1.5 [0.6–4.5] < 0.01 STS score (Median[IQR]) 4.6 [2.4–16.5] 4.2 [1.1–9.0] 2.0 [0.8–6.0] < 0.01 GNRI (Median[IQR]) 89.3 [80.6–90.8] 87.3 [75.9–95.3] 98.3 [90.8–98.3] < 0.01 Clinical Frailty Scale (Median[IQR]) 5 [4-7] 3.0 [3.0 – 5.0] 3.0 [2.2 – 3.8] < 0.01 Comorbidity, n(%) DM 20 (90.9) 26 (63.4) 152 (56.1) < 0.01 HD 19 (86.4) 11 (26.8) 32 (11.8) < 0.01 HTN 11 (50.0) 35 (85.4) 215 (79.3) < 0.01 DLP 12 (54.6) 20 (48.8) 194 (71.6) < 0.01 Prior PCI 8 (36.4) 17 (41.5) 67 (24.7) 0.05 Preoperative IABP 3 (13.6) 3 (7.3) 12 (4.4) 0.10 Preoperative ECMO 3 (13.6) 0 11(4.1) 0.05 Preoperative IMPELLA 1 (4.6) 0 4 (1.5) 0.38 Preoperative shock 3 (13.6) 2 (4.9) 22 (8.1) 0.50 AMI 3 (13.6) 3 (7.3) 22 (8.1) 0.59 WIfI classification Wound grade, 0/1/2/3 2/6/9/5 Ischemia grade, 0/1/2/3 0/3/4/15 Foot infection grade, 0/1/2/3 1/9/11/1 Wifi clinical stage, 1/2/3/4 0/4/4/14 Echocardiography Ejection fraction, ±SD % 43.2 ± 14.6 48.1 ± 12.5 50.9 ± 13.2 0.02 CAD SVD 0 (0) 3 (7.3) 19 (7.0) 0.44 DVD 3 (13.6) 8 (19.5) 63 (23.2) 0.53 TVD 19 (86.4) 30 (73.2) 189 (69.7) 0.24 Urgency, n(%) Elective 14 (63.6) 28 (68.3) 246 (90.8) < 0.01 Urgent 6 (27.3) 3 (7.3) 6 (2.2) < 0.01 Emergent 2 (9.1) 10 (24.4) 19 (7.0) < 0.01 BMI: body mass index, GNRI: geriatric nutritional risk index, DM: diabetes mellitus, HD: hemodialysis, HTN: hypertension, DLP: dyslipidemia,PCI: percutaneous coronary intervention, IABP: intra-aortic balloon pumping, ECMO: extracorporeal membrane oxygenation, AMI: acute myocardial infarction, WIfi: Wound, Ischemia, and foot Infection, SVD: single vessel disease, DVD: double vessel disease, TVD: triple vessel disease 13 Surgery Today was higher in the Non-CLTI LEAD group; and SVG use was lower in the CLTI group (all p < 0.01). The total number of grafts differed significantly among the groups (p < 0.01), with the fewest grafts in the CLTI group and the most in the Non-LEAD group; the rate of distal anastomosis count was similar (p = 0.59). Complete revascularization was less frequent in the CLTI group (p < 0.01). No planned staged percutaneous coronary intervention (PCI) or hybrid revascularization was performed in the CLTI group. The two cases of repeat revascularization in the CLTI group were unplanned emergency interventions due to acute graft occlusion identified on postoperative imaging; one patient underwent PCI and the other underwent redo CABG. Reasons included prior SVG use for distal bypass (n = 3), planned post-CABG distal bypass (n = 1), or procedural invasiveness (n = 3; one MIDCAB for pyoderma with moderate AS, one LAD-only due to diffuse aortic calcification, one LAD/ LCX-only due to cardiogenic shock in triple-vessel LMT disease). Aortic cross-clamp time differed significantly; other operative times were similar. LEAD-related interventions were more frequent in the CLTI group (all p < 0.01). Postoperative outcomes are summarized in Table 3. Thirtyday mortality was similar among the groups; however, repeat revascularization and hospital stay were higher in the CLTI group (p < 0.01). Early graft occlusion rates were 4.8% (1/21) in the CLTI group, 7.5% (3/40) in the Non-CLTI LEAD group, and 2.7% (7/263) in the Non-LEAD group Table 2 Operative data Variable CLTI group n=22 (p = 0.27). Within the CLTI group, postoperative outcomes did not differ significantly between MIDCAB and sternotomy CABG (Table 4) or between complete and incomplete revascularization (Table 5). Five-year survival (Fig. 2) was significantly lower in the CLTI group, with no difference between Non-CLTI LEAD and Non-LEAD. Similarly, the Kaplan–Meier analysis revealed that the 5-year freedom from MACCE rate (Fig. 3) was significantly worse in the CLTI group than in the other groups (p < 0.01). The overall follow-up completeness rate was 90.7% (100% in the CLTI group, 90.2% in the Non-CLTI LEAD group, and 90.0% in the Non-LEAD group). Cox analysis (Fig. 4) showed that age, hemodialysis, and AMI independently predicted longterm mortality; limb status was not independently associated. MACCE (Table 6), including cardiac death, were significantly more frequent in the CLTI group. Within the CLTI group, long-term MACCE and its components did not differ significantly by surgical approach (Table 7) or by completeness of revascularization (Table 8). Discussion Long-term survival after isolated CABG was significantly poorer in CLTI patients than in those with stable LEAD or without LEAD, although CLTI was not an independent risk factor in multivariable analysis. Non-CLTI LEAD group n=41 Non-LEAD group n=271 P-value CABG Median sternotomy 18 (81.8) 39 (95.1) 262 (96.7) < 0.01 Left mini-thoracotomy 4 (18.2) 2 (4.9) 9 (3.3) < 0.01 On pump arrest 13 (59.1) 22 (53.7) 207 (76.4) < 0.01 On pump beating 4 (18.2) 10 (24.4) 33 (12.2) 0.09 Off pump 5 (22.7) 9 (22.0) 31 (11.4) 0.08 BITA 7 (31.8) 15 (36.6) 39 (14.4) < 0.01 SITA 15 (68.2) 25 (61.0) 210 (77.5) 0.06 SVG 11 (50.0) 28 (68.3) 231 (85.2) < 0.01 GEA graft 0 (0) 2 (4.9) 13 (4.8) 0.58 Number of distal anastomoses, median [IQR] 3.0 [2.0, 3.75] 3.0 [2.0, 3.0] 3.0 [2.0, 4.0] 0.59 Total graft number, median [IQR] 2.0 [2.0, 2.0] 2.0 [2.0, 2.0] 2.0 [2.0, 3.0] < 0.01 Complete revascularization 15 (68.2) 39 (95.1) 263 (97.0) < 0.01 CPB time, mean ±SD min 155 ± 123 120 ± 42 149 ± 55 0.09 AXC time, mean ±SD min 80 ± 41 83 ± 34 101 ± 37 0.03 Operation time, mean ±SD min 303 ± 101 308 ± 93 318 ± 90 0.53 PAD Major amputation 2 (9.1) 1 (2.4) 0 < 0.01 Distal bypass 12 (54.6) 1 (2.4) 0 < 0.01 SVG graft 11 (50.0) 1 (2.4) 0 < 0.01 EVT 19 (86.4) 13 (31.7) 0 < 0.01 CABG: coronary artery bypass grafting, BITA: bilateral internal thoracic artery, SITA: single internal thoracic artery, SVG: saphenous vein graft, GEA: gastroepiploic artery CPB: cardio pulmonary bypass, AXC: aortic cross-clamping, PAD: peripheral artery disease EVT: endovascular treatment 13 Surgery Today Table 3 Postoperative outcomes Variable 30 days mortality, n (%) Stroke Prolonged ventilation Deep sternal wound infection Reoperation for bleeding Permanent Pacemaker Repeat revascularization Early graft occlusion, n/N (%) ICU stay, mean±SD days Hospital stay, ±SD days ICU: intensive care unit CLTI group n=22 2 (9.1) 1 (4.6) 1 (4.8) 2 (9.0) 1 (4.6) 0 (0) 2 (9.1) 1/21 (4.8) 7.7 ± 6.9 37.4 ± 35.1 Non-CLTI LEAD group n=41 1 (2.4) 1 (2.4) 0 (0) 2 (4.9) 0 (0) 0 (0) 5 (12.2) 3/40 (7.5) 4.2 ± 3.0 30.6 ± 28.1 Table 4 Postoperative outcomes – CLTI: MICS vs Sternotomy Variable MICS n=4 30-day mortality, n (%) 0 (0) Stroke, n (%) 0 (0) Prolonged ventilation, n (%) 0 (0) Deep sternal wound infection, n (%) 0 (0) Reoperation for bleeding, n (%) 0 (0) Permanent Pacemaker, n (%) 0 (0) Repeat revascularization, n (%) 1 (25.0) Early graft occlusion, n/N (%) 0/4 (0) ICU stay, mean±SD, days 3.0 ± 1.4 Hospital stay, mean±SD, days 15.2 ± 5.7 MICS: minimally invasive cardiac surgery, ICU: intensive care unit Non-LEAD group n=271 16 (5.9) 9 (3.3) 8 (3.0) 6 (2.2) 3 (1.1) 2 (0.7) 4 (1.5) 7/263 (2.7) 5.7 ± 8.8 22.4 ± 20.7 Sternotomy n=18 2 (11.1) 1 (5.6) 1 (5.9) 2 (11.1) 1 (5.6) 0 (0) 1 (5.6) 1/17 (5.9) 8.7 ± 7.2 41.9 ± 37.1 P-value 0.52 0.90 0.46 0.15 0.27 0.79 < 0.01 0.27 0.08 < 0.01 P-value 1.00 1.00 1.00 1.00 1.00 1.00 0.39 1.00 0.05 0.12 CABG, coronary artery bypass grafting; CLTI, chronic limb-threatening ischemia; MIDCAB, minimally invasive direct coronary artery bypass Table 5 Postoperative outcomes – CLTI: complete revasucularization vs Incomplete revascularization Variable Complete revascularization Incomplete revascularization n=15 n=7 30-day mortality, n (%) 1 (6.7) 1 (14.3) Stroke, n (%) 0 (0.0) 1 (14.3) Prolonged ventilation, n (%) 1 (7.1) 0 (0.0) Deep sternal wound infection, n (%) 1 (6.7) 1 (14.3) Reoperation for bleeding, n (%) 1 (6.7) 0 (0.0) Permanent Pacemaker, n (%) 0 (0.0) 0 (0.0) Repeat revascularization, n (%) 1 (6.7) 1 (14.3) Early graft occlusion, n/N (%) 0/14 (0.0) 1/7 (14.3) ICU stay, mean±SD, days 8.5 ± 7.7 5.9 ± 4.9 Hospital stay, mean±SD, days 38.1 ± 39.2 34.9 ± 27.0 ICU: intensive care unit P-value 1.00 0.32 1.00 1.00 1.00 1.00 1.00 0.33 0.43 0.94 CLTI, chronic limb-threatening ischemia Operative strategies for LEAD patients Surgical strategy in LEAD patients should be individualized based on comorbidities and anatomy. LEAD is commonly associated with diabetes, dialysis-dependent renal failure, and cerebrovascular disease, increasing the operative risk [8–13]. Optimal graft selection and extent of revascularization remain controversial. Bianco et al. demonstrated that complete revascularization improved 5-year survival (86.5% vs. 82.1%) and reduced the risk of MACCE (hazard ratio, 0.82; 95% CI, 0.70–0.95) [14]. In our study, complete revascularization rates were 68.2% (CLTI), 95.1% (Non-CLTI), and 97.0% (Non-LEAD). In CLTI, conduit selection is often limited by lower-extremity 13 Surgery Today revascularization needs; prior studies showed no 10-year survival difference between bilateral and single internal thoracic artery grafting in LEAD [13]. The comparable long-term survival between the Non-CLTI LEAD and NonLEAD groups supports aggressive revascularization when feasible in LEAD without CLTI. Risk stratification beyond binary LEAD classification Fig. 2 Kaplan–Meier estimates of long-term survival. Five-year survival was significantly lower in the CLTI group than in the Non-CLTI LEAD and Non-LEAD groups (p < 0.01). CLTI, chronic limb-threatening ischemia; LEAD, lower extremity arterial disease Preoperative risk scores differed among groups (p < 0.01); however, 30-day mortality did not, whereas 5-year survival and MACCE were significantly worse in the CLTI group. Current models treat LEAD as a single entity and predict only 30-day mortality, failing to capture long-term differences. In the SPINACH registry, 2-year survival was 64.9%, with older age, low BMI, renal failure, heart failure, and higher WIfI grade as independent predictors, stratifying 2-year survival from >90% to ~20% [5]. Setogawa et al. reported that the SPINACH SCORE and GNRI better predict mid-term outcomes than the Japan SCORE [15]. In our cohort, the 5-year survival rates in the CLTI, Non-CLTI LEAD, and Non-LEAD groups were 39.8%, 86.2%, and 90.8%, respectively, with no significant difference between the latter two groups, highlighting the markedly poor prognosis of CLTI after cardiac surgery. Heterogeneity of CLTI severity Fig. 3 Kaplan–Meier estimates of freedom from major adverse cardiac and cerebrovascular events (MACCE). The 5-year freedom from MACCE rate was significantly lower in the CLTI group compared with the Non-CLTI LEAD and Non-LEAD groups (p < 0.01). CLTI, chronic limb-threatening ischemia; LEAD, lower extremity arterial disease; MACCE, major adverse cardiac and cerebrovascular events Fig. 4 Forest plot of multivariable Cox proportional hazards analysis for 5-year survival. Age, HD, and AMI were independent predictors of long-term mortality. Squares, HRs; lines, 95% CIs. AMI, acute myocardial infarction; CI, confidence interval; HD, hemodialysis; HR, hazard ratio 13 CLTI encompasses a broad spectrum of limb threats. The WIfI classification has been widely adopted to quantify this heterogeneity; higher WIfI stages are associated with increased mortality and major adverse limb events [16]. The limited CLTI cohort size (n = 22) precluded WIfI-based Surgery Today Table 6 Postoperative MACCE Variable CLTI group Non-CLTI LEAD group Non-LEAD group n=22 n=41 n=271 Median follow-up (IQR) days 585 [105–998] 1445 [774–1886] 1168 [360–2084] MACCE, long-term, n (%) 12 (54.6) 7 (17.1) 46(17.0) Cardiac death 3 (13.6) 0 (0) 11 (4.1) Cerebrovascular accident 1 (4.6) 1 (2.4) 7 (2.6) HF requiring hospitalization 1 (4.6) 1 (2.4) 2 (0.74) Postoperative MI 1 (2.6) 1 (2.4) 4 (1.5) All-cause death 13 (59.1) 5 (12.2) 24 (8.9) MACCE: major adverse cardiac and cerebrovascular events, HF: heart failure, MI: myocardial infarction P-value 0.02 < 0.01 0.04 0.86 0.54 0.55 < 0.01 Table 7 Postoperative MACCE– CLTI: MICS vs Sternotomy Variable MICS Sternotomy P-value n=4 n=18 Median follow-up (IQR) days 1425 [622–2430] 525 [90–720] 0.10 MACCE, long-term, n (%) 2 (50.0) 10 (55.6) 1.00 Cardiac death 0 (0) 3 (16.7) 1.00 Cerebrovascular accident 0 (0) 1 (5.6) 1.00 HF requiring hospitalization 0 (0) 1 (5.6) 1.00 Postoperative MI 0 (0) 1 (5.6) 1.00 All-cause death 2 (50.0) 11 (61.1) 1.00 MICS: minimally invasive cardiac surgery, MACCE: major adverse cardiac and cerebrovascular events, HF: heart failure, MI: myocardial infarction CABG, coronary artery bypass grafting; CLTI, chronic limb-threatening ischemia; MACCE, major adverse cardiac and cerebrovascular events; MIDCAB, minimally invasive direct coronary artery bypass Table 8 Postoperative MACCE– CLTI: complete revasucularization vs Incomplete revascularization Variable Complete Incomplete P-value revascularization revascularization n=15 n=7 Median follow- 605 [315–1170] 330 [64–555] 0.231 up (IQR) days MACCE, long- 8 (53.3) 4 (57.1) 1.000 term, n (%) Cardiac death 3 (20.0) 0 (0.0) 0.523 Cerebrovascular 0 (0) 1 (14.3) 0.32 accident HF requiring 1 (6.7) 0 (0) 1.00 hospitalization Postoperative MI 0 (0) 1 (14.3) 0.32 All-cause death 8 (53.3) 5 (71.4) 0.65 MACCE: major adverse cardiac and cerebrovascular events, HF: heart failure, MI: myocardial infarction CLTI, chronic limb-threatening ischemia; MACCE, major adverse cardiac and cerebrovascular events stratification, but greater limb severity likely contributed to worse outcomes. Future larger studies should examine the relationship between WIfI severity, completeness of revascularization, and early mortality. The dilemma of complete revascularization in CLTI The rate of complete revascularization was lower in the CLTI group (68.2%) than in the Non-CLTI LEAD (95.1%) and Non-LEAD (97.0%) groups, reflecting a deliberate strategy to limit operative invasiveness and preserve the saphenous vein for distal bypass. Despite incomplete revascularization, 30-day mortality and mediastinitis did not differ between the groups. However, given the small CLTI cohort (n = 22) and the limited number of patients who underwent incomplete revascularization (n = 7), this finding should not be interpreted as wsuggests only that our tailored, less-invasive strategy did not appear to compromise early safety in this highly selected population, an observation that requires confirmation in larger studies. Notably, 54.6% of CLTI patients subsequently underwent limb-salvage surgery, confirming CABG as an effective bridge to limb preservation. Long-term prognosis and the "Heart-Limb Team" strategy Patients with stable LEAD had long-term survival comparable to that of non-LEAD, likely reflecting strict preoperative selection by the Heart-Limb Team (i.e., only patients judged capable of tolerating CABG were referred) and should undergo equally aggressive revascularization. The 5-year survival of ~40% in our predominantly hemodialysis 13 Surgery Today (86.4%) CLTI cohort may appear favorable relative to general CLTI populations, likely attributable to the relatively young mean age (66.3 years) and rigorous preoperative selection. Additionally, within the CLTI cohort, major amputation occurred in 1 of 15 patients (6.7%) who underwent complete revascularization and in 1 of 7 patients (14.3%) who underwent incomplete revascularization (p = 1.00). Although limited by the small sample size, these findings suggest that our strategy of intentionally restricting coronary revascularization to preserve the saphenous vein did not adversely affect limb salvage. Limitations This study has several limitations. Its retrospective, singlecenter design limits generalizability. The small CLTI cohort (n = 22) reduced statistical power, increasing the risk of type II error. A substantial preoperative selection bias is inherent in our Heart-Limb Team strategy, whereby only patients deemed capable of tolerating CABG were referred for surgery. Although we do not have a precise retrospective headcount of patients who were deemed ineligible for initial CABG, our multidisciplinary Heart-Limb Team conducted rigorous screening at the initial conference stage; patients with prohibitive surgical risk, profound frailty, or uncontrollable active systemic infection (e.g., severe foot osteomyelitis requiring urgent primary amputation) were directed toward endovascular therapy or palliative management rather than CABG. Because these patients were excluded at the pre-operative conference stage, they were not captured in our surgical cohort, representing an inherent and unquantifiable selection bias in this study. Substantial heterogeneity existed within the CLTI cohort regarding operative strategy and completeness of revascularization. To address this directly, we performed subgroup analyses stratifying the CLTI group by surgical approach (MIDCAB vs. sternotomy CABG; Tables 4 and 7) and by completeness of revascularization (Tables 5 and 8). No statistically significant differences were observed in postoperative outcomes or long-term MACCE between these subgroups; however, given the very small subgroup sizes, particularly the MIDCAB (n = 4) and incomplete revascularization (n = 7) subgroups, these analyses are substantially underpowered, and the absence of statistically significant differences should not be interpreted as evidence of equivalence or as support for the safety of these approaches. WIfI-based stratification was not feasible due to the limited sample size and incomplete data; thus, the impact of limb ischemia severity could not be fully adjusted. Although we captured frailty using the Clinical Frailty Scale (Table 1), other residual confounders, such as detailed nutritional 13 status beyond the GNRI, could not be fully accounted for given the small sample size. Conclusion CLTI is a significant predictor of a poor long-term prognosis after CABG. In high-risk CLTI patients, a strategy prioritizing operative safety and conduit preservation may yield incomplete revascularization; in our small cohort, this did not appear to compromise short-term outcomes, although this observation is hypothesis-generating and requires confirmation in larger studies given the limited statistical power. More than half of the CLTI patients subsequently underwent limb-salvage procedures, confirming that CABG serves as a vital physiological bridge to limb preservation in this fragile population and underscoring the value of a multidisciplinary heart-limb team approach. Acknowledgements None Funding The authors have no funding sources to disclose. Declarations Conflicts of interests N.A. is a member of an endowed department supported by AIN Holdings Inc. All other authors declare no conflicts of interest in association with this study. Ethical approval This study was approved by the Ethics Committee of our hospital on April 13, 2023 (approval no. 22161). Owing to the retrospective observational design, the requirement for informed consent was waived by the Ethics Committee. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit ​h​t​t​​p​:​/​/​​c​r​e​​a​t​i​​v​e​c​o​m​m​o​n​s​.​o​ r​g​/​l​i​c​e​n​s​e​s​/​b​y​/​4​.​0​/​​​​.​​ References 1. 2. Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009;204(2):e86–92. Fowkes FG, Low LP, Tuta S, Kozak J. AGATHA Investigators: Ankle-brachial index and extent of atherothrombosis in 8891 Surgery Today 3. 4. 5. 6. 7. 8. 9. patients with or at risk of vascular disease: results of the international AG-ATHA study. Eur Heart J. 2006;27:1861–7. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(Suppl 1):S1-75. ​h​t​t​​p​s​:​/​​/​d​o​​i​.​o​​r​g​/​1​0​.​1​0​1​6​/​j​.​e​j​v​s​.​2​0​0​6​.​0​9​.​0​ 2​4​​​​.​​​ Kikuchi S, Sasajima T, Inaba M, Uchida D, Kokubo T, Saito Y, et al. Evaluation of paramalleolar and inframalleolar bypasses in dialysis- and nondialysis-dependent patients with critical limb ischemia. J Vasc Surg. 2018;67(3):826–37. ​h​t​t​p​s​:​/​/​d​o​i​.​o​​r​​​g​/​​1​​0​.​1​0​ 1​6​/​j​.​j​v​s​.​2​0​1​7​.​0​7​.​1​1​6​​​​.​​​ Azuma N, Takahara M, Kodama A, Soga Y, Terashi H, Tazaki J, et al. Predictive model for mortality risk including the wound, ischemia, foot infection classification in patients undergoing revascularization for critical limb ischemia. Circ Cardiovasc Interv. 2019;12(12):e008015. Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S-12S. e40. Lawton JS, Tamis-Holland JE, Bangalore S, Bate ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. J Am Coll Cardiol. 2022;79(2):e21–129. Farkouh ME, Rihal CS, Gersh BJ, Rooke TW, Hallett JW Jr, O’Fallon WM, et al. Influence of coronary heart disease on morbidity and mortality after lower extremity revascularization surgery: a population-based study in Olmsted County, Min-nesota (1970–1987). J Am Coll Cardiol. 1994;24:1290–6. Chu D, Bakaeen FG, Wang XL, Dao TK, LeMaire SA, Coselli JS, et al. The impact of peripheral vascular disease on long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg. 2008;86:1175–80. 10. van Straten AHM, Firanescu C, Soliman Hamad MA, Tan MESH, Woorst JFJ, Martens EJ, et al. Peripheral vascular disease as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population. Ann Thorac Surg. 2010;89:414–20. 11. Efird JT, O’Neal WT, O’Neal JB, Ferguson TB, Chitwood WR, Kypson AP, et al. Effect of peripheral arterial disease and race on survival after coronary artery bypass grafting. Ann Thorac Surg. 2013;96:112–8. 12. Cassar A, Poldermans D, Rihal CS, Gersh BJ. The management of combined coronary artery disease and peripheral vascular disease. Eur Heart J. 2010;31:1565–72. 13. Nakatsu T, Tamura N, Yanagi S, Kyo S, Koshiji T, Sakata R. Bilateral internal thoracic artery grafting for peripheral arterial disease patients. Gen Thorac Cardiovasc Surg. 2014;62:481–7. 14. Bianco V, Kilic A, Aranda-Michel E, Serna-Gallegos D, Ferdinand F, Dunn- Lewis C, et al. Complete revascularization during coronary artery bypass grafting is associated with reduced major adverse events. J Thorac Cardiovasc Surg. 2022;164(4):1002–10. 15. Setogawa Y, Kikuchi S, Oyama K, Tsutsui M, Azuma N, Kamiya H, et al. Mid-term mortality prediction using four established risk scores in patients with chronic limb-threatening ischemia undergoing cardiac surgery. J Clin Med. 2025;14(17):6210. https:​​​//d​oi.​ or​g/10​.339​0/jcm14176210. 16. Wakabayashi N, Kikuchi S, Kuriyama N, Kikuchi Y, Tsutsui M, Ise H, et al. The impact of chronic limb-threatening ischemia on cardiac surgery. Front Surg. 2022;9:892309. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. 13